Walden University NURS 6630 WEEK 5 ASSIGNMENT Walden University NURS 6630 WEEK 5 ASSIGNMENT WK5assignlemmercml5 Case study week 5 PTSD Walden University NURS 6630 WEEK 5 ASSIGNMENT Walden University N

************************** ***** week 5 *********** ************ UniversitySeptember ** ************************** ***** **** 5 **** **** ***** ** * ************* ************ ** ***** medication alternatives **** can ** prescribed *** *** ******* ********* from PTSD It ***** ***** ******* *** the particular decisions **** ***** ***** **** indicating **** was ******** **** ** with * ******** analysis ** *** ********** and chemical ******* ** the ********** medication in the ***** In the *** ** ******** * ********** between **** *** expected *** **** has been ******** ** the patientDecision ******* ******** did *** select?Based ** the *********** background I ***** ** ***** ****** ** ** ****** ******** *** *** ****** **** ********* *** ******* ******** ******** ** ******* ******** ***** can be *********** ******* ******* *************** ** this case Zoloft ** ********** ********* reuptake inhibitor ****** drug ***** ** ******** ********** *** a ****** ** *********** disorders including ****** ******* ********** and ********* compulsive ******** among ****** (Stahl 2013) ********* *** *** of ****** *** **** ******* ** ********* ** *** **** **** ** **** ********** *** ******** ********* with ***** ********* ** a **** **** ** can **** in ********** ** **** ********* ** *** *********** ***** This ** * ******** *********** **** ******* ******* **** *** brain ******* ********** *** ********** ** ********* *********** *** ******** ******** ** ** **** ** ****** *** ************* ** *** ******** ********* ** the brain ****** it ** ** ********* ** ****** *********** ***** *** ********* ** ***** *********** ** they **** tend ** primarily ****** ********* rather **** any ***** transmitters ******** ** *** other *********** Zoloft ************ *** ******* attacks ***** ** **** ** improvement particularly in *** ********* ** baseline symptoms ********** **** ******* * *** *** **************** **** *** ******* ** ** ******* effective ** treating ********** and generalized ******* Further ** *** **** ****** **** ******* such ** irregular rhythms *** *********** ******* failure ** even ****** ***** The **** is mostly used ** combination with others ** ***** *********** ** ***** ***** it ** **** used *** ********** ***** ** could **** *** patient ** improvehis **** ******** ** *********** ******** in ***** living ******* ** ***** *** help ** ********** ********* in *** **** Additionally *** patient ***** beer ***** the Imipramine drug * **************** **** ** ******* *** drug is an ************** ******** **** *** ****** ** further ******** *** ********** ********* ********* **** BID *** **** ********* *** it was *** *********** *** the ******* ******* ******** ***** *********** ** *** ******* ****** & ***** ***** **** ** because ********* is mostly **** for *********** ******* ***** is not **** *** ******* is experiencing *********** ** ** ******** ********* *********** **** ** ******** anxiety to ******* *** ***************** were you ****** ** achieve ** making this decision? ****** *** benefit *** ******* by ********** *** ********* and *** ******** ** ********* of ****** which ** ****** ***** ** a ****** of ******* ****** 2013) As ** **** ****** increases *** ****** of ********* in *** brain ** * result it causes *** brain ** have * ******** state ** ********* ***** ** responsible for ********** mood *** ******* **** is **** intended ** ****** *** patient **** ********* ** *** ***** ** **** ** worries ***** ********* *** generally associated with **** ******* of stress that *** ****** in *** depletion ** *** ********* levels **** ** *** reason Zoloft ** mostly ********** ** ** *************** ***** **** **** *************** Zoloft the patient is ******** ** ***** ******* **** ******* about **** ** *** ***** thing ********* ** ***** *************** ** *** ******* neurotransmitter *********** for *** ****** ** *** ******** *** CSTC ******** that *** *********** for ********** **** and *********** ********* **** ***** **** ** Zoloft is ************ ** **** **** ** inhibiting *** serotonin *********** ****** ***** **** ******** *** output ** serotonin and ******** symptoms of ***** ** **** **** can especially ** ***** ** *** client ** this **** ************ **** ************ *** *********** is to **** to regulate the ******** ** the ******* ** ****** **** ** ******* his ****** *********** any ********** ******* **** *** expected to achieve **** ******** ** *** the ******* ** *** ******** Why **** **** different? ****** **** ***** *** ****** reported * *********** change in *** ****** ****** ***** *** ********** ** anxiety ******* had drastically ******* **** ***** **** *** Zoloft 50mg ***** ****** was ********* ** *** ******* ***** *********** *** ********* in *** breath ** tightness ** *** ***** This response ** themedication was significantly **** ***** the ******** response ********* the medication *** ******* effectively as *** *********** HAM-A ***** decreasedfrom ** to ** **** ***** ** the ***** of **** to ******** ******* ******* ********* 1959) **** ***** **** ******** ** the ********* and **** *** result ** the ********** of anxiety *************** ******* decision *** you ********** second ******** ****** was ** continue **** ****** ********** but ********** the ****** **** 50mg/day to 75g/day This *** due ** the ******** ******** ****** ** the patient ** *** ******* *** you select this ********* *** ****** made ** **** **** *** ** continue *** **** ********** *** ********** *** ****** ****** **** **** *** *** ** ***** ******** The ****** for ********** *** ****** *** informed ** *** fact that the ******* ********* effectively ** the ******* **** **** *** *** ******* better ** *** ****** ****** ** ********* Stahl (2013) contends **** *** ****** dosage *** ** ********* ***** ** ** ***** for *** first *** ***** in *** ***** ** *** not ********* *** therapeutic ******* In **** **** ******* *** ******* *** ********* ********** ** *** medication ******* that ** ** working correctly ** **** ****** *** ******** ** increase *** ****** ** based on the fact **** *** ******* ***** **** ******* ****** **** ** ******** Zoloft ****** ** about ******** (Strawn ** ** ***** This ** ***** ** *** **** that *** ******* **** continue ** ******* *********** improvement ** *** ********* ********** *** ****** ** the ********** to ********* of ****** *** *** * ****** *********** due to *** *********** ** causing ***** side **************** ********* 2016g) ******* *** ****** should ** ********* ********* to monitor *** body ******** *** ********* **** ******* Therefore this **** ***** **** ****** subjected *** patient ** ********* major side ******* **** range **** ********** ** reduced ***** ******** **** *** hoping to achieve ** making **** ********* **** *** ******** ** *** patient ** *** 50mg/day ****** ** was ***** that the ***** ******* ***** ****** ** ********* ** ********** *** ****** Prolonged ****** ** ********** ** ***** ***** ********* **** ****** ** reduction of serotonin ****** ********* ** ********* ****** ** Zoloft would **** to ************* in ********** of *** ************* ** serotonin ** *** ***** ******* to **** ********* ********* ** ******** most ** *** ****** ****** ** ** *** ** ** ****** ***** experience ******* ********* *** ******** ** ***** attacks ********* increasing *** ****** ***** ************* result in reduction ** ******** ******* *** **** ****** ****** ** further ********** to ** ********* **** cognitive ********** therapy ********* Education ****** ***** 2013)Explain any ********** ******* what *** ******** ** ******* **** ******** ** and *** ******* of *** decision **** *** ********* Zoloft dosage ** **** *** **** weeks ***** was * *********** *********** on the ******* symptoms ** ***** *** ***** ** this **** *** ******* could ****** ** the ********** *** a further ******** ** **** ***** ********* **** ********* ** *** *** ******** ************ **** ******* ******* from *** ******** outcome ** *** prescription particularly on *** **** ******* **** *** onset the ******** of ****** ****** ** 75mg/day *** considered ****** detrimental ** ** ***** ****** ** ****** **** ******* ******* the patient ***** ** **** *********** ** side ******* ***** on *** ******* ** ** highly unlikely that *** panic ******* **** ******* as *** ********** ***** ** be ****** ***************** ******* decision *** you select?The ******** selected ** this ***** *** to continue with *** ******* **** ****** ****** as ** *** effective ** *** ****** Also attempts ** ******** *** ****** ***** have ******** ** ***** **** ********** *** *** ****** **** decision? The ****** ** ****** on *** ******* ********* **** *** ******** ** the ************* ** presented on the ******* outcome ***** the ******* of *** ****** **** ** ** ** ** of ****** *** day the ****** ***** ** **** improved *** ********** overall position and *** ******** *** ******* by *** This *********** majorchange that ***** not ** simply interrupted ** * possible ******** ** dosage ***** ** ** ***** *********** *** *** improvement that *** ****** experienced *** without *** side ******* *** *********** ******* of ****** *** *** ****** **** ******** was selected ** was not wise ** ******** the dosage to ********* ** *** **** ********** due to the ********* of ******** severe **** ******* This is ******* *** ******* ****** *** **** ********* in ********* *** ********* ** *** ****** Also *** option ** combining ****** **** augmentin *** *** ********* ******* of *** ********* ** *** *** ***** ********* ** ****** antibiotic ** ****** and the ****** was not ********* **** any viral or ********* infection Therefore **** *********** ***** have **** *********** ** ***** ***** ***** ******** ******** ** **** *********** were *** hoping ** ******* ** ****** **** ********* *** *********** was ** ******* *** **** ******* ** ** *** **** **** **** ********** ****** ********* ****** ** ****** ** ******* the ******* ******** ********* in *** ******** ** anxiety (Stahl ********* *** ******* performance of the ********** ** the current **** was largely effective *** appropriate *** *** ************* *** difference ******* **** *** ******** ** ******* with Decision #3 *** *** ******* ** the ******** *** were they ********** The ******* of the ********* *** ** ****** ******** ** *** ******* was ******* ******** of ***** ******* and general ****** ****** *** *********** *** **** *** patient ***** ******** ** ******* *** *** *********** ** relapse *** ********** ******* the outcome *** not ******** ** ** *********** ** ** *** **** ** ***** *** client *** ********* for ******** **** ******* as ** ********* ** *** the medication Surprisingly *** *** patient symptoms **** ** **** *** the ******* ****** *************** Considerations From *** **** study *** patient is a Caucasian *** born *** ****** ** the ** Despite **** ** ** important ** consider that different ****** groups manageanxiety ********* ** different ways ** **** **** *** **** ** ****** ****** *** ******* ********** ****** apply to ****** **** the ******* is *** ********** **** means ************ * **** ****** ** *************** **** ** ***** ********** sensitive towards *** *********** ******** ********* ** ****** ********** *********** (2017) ** is important for clinicians to *** close ********* ** *** patient’s ******** ** **** ** ******** decision ***** their ****** **** ** largely important **** ****** changes on *** ****** of the medications *** ******* ****** ** ******** ** *** these ***** ****** they *** *********** and *** autonomy ****** not ** ********* ** **** ******************************************************************************** Psychiatric Association ****** ********** and *********** ****** ** mental ********* **** *** ********** *** AuthorBeeker * ********** T * &Coenen * * (2017) ******** ** depressive ******** undergoing ************** ******** ******* freedom ** will and ****** potential to restore *********** in *********** ************** ** ******************************************* * ****** ******** Anxiety Rating ***** ********* **** 101037/t02824-0Laureate ********* ******* **** Study: ** ******* ******** Man with ***** Depressive ******** ************* ***** ***** ********* *** ********** M Martinotti * Acciavatti * ********** * Brunetti * ********** * ***** ** ************ * ****** *************** ********** ** ******** ********* * *********** review Biomed ******** International **** ************************** S * ***** Grady M ****** ********* illustrated ******* ****** *** **** *** **** *** ********* ********** ********** * * ****** ********* ********* ******************* *************** ***** *** ********* applications **** *** New **** *** ********* ********** *********** J * ** ** (2012) Establishing *** ************* ***** ** ********* ** children and *********** **** *********** ******* ******** Depression *** ******* 29(4) 328–-339 ******************

Click here to download attached files: docx-(4).docx